Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2007-4-3
pubmed:abstractText
Recruited bone marrow-derived circulating cells (RBCCs) play a key role in therapeutic neovascularization. Several important steps take place during this process, which include mobilization, migration, recruitment, adhesion and invasion, entrapment, differentiation, as well as paracrine functions. Recent study indicated that recruitment and entrapment of RBCCs are vital steps in vascular endothelial growth factor (VEGF)-induced angiogenesis. This entrapment is modulated by another important chemokine: stromal derived factor 1 (SDF-1). We reason that the enhancement of entrapment might be a novel target for therapeutic neovascularization. Therefore we hypothesize that mesenchymal stem/stromal cells that secrete VEGF in situ could be transfected with SDF-1 (MSC(SDF-1)). Their combination could augment mobilization, recruitment, survival, and above all the entrapment of RBCCs, all of which might greatly augment the angiogenesis pathway. For these reasons, we further hypothesize that MSC(SDF-1) might become a next generation cell/chemokine therapy for therapeutic neovascularization.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:issn
0306-9877
pubmed:author
pubmed:issnType
Print
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1268-71
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
2007
pubmed:articleTitle
Mesenchymal stem/stromal cells (MSC) transfected with stromal derived factor 1 (SDF-1) for therapeutic neovascularization: enhancement of cell recruitment and entrapment.
pubmed:affiliation
Department of Cardiology, Children's Hospital Boston, Harvard Medical School, Enders 13, 300 Longwood Avenue, Boston, MA 02115, USA. bzhou@enders.tch.harvard.edu
pubmed:publicationType
Journal Article